Verge Genomics
YC S15 ↗San Francisco, US · Founded 2015 · 50 employees · 11 known investors
Verge Labs builds AI models trained on multimodal human patient data to predict drug targets and patient populations for clinical development, primarily in neuroscience and central nervous system (CNS) disease. The company applies frontier AI techniques to drug discovery for life sciences and pharmaceutical development.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtechin /verge-genomics/@vergegenomicsycombinator.com ↗
Founders & leadership· Y Combinator alumni (S15)
AZ
ER
Emily RipkaHead of Product & Engineering
JC
Jason ChenCofounder30 Under 30 2020
Investors · 11
BOLD LongevityBoston
Great Oaks Venture CapitalNew York · $50K – $500K
Karlin VenturesLos Angeles · $250K – $2M
Lifeforce CapitalChevy Chase · $500K – $5M
Tenmile
WorldQuant VenturesOld Greenwich
Y CombinatorSan Francisco · $500K
Agent CapitalreportedWaltham
Basis Set VenturesreportedMenlo Park · $1M – $3M
Fitz Gate VenturesreportedHouston · $500K – $1M
OS FundreportedPark Ridge · $1M – $2M
In the news
- Where Are They Now: Verge Genomics | Science | AAASscience.org · 2025
- Sell or Invest in Verge Genomics Stock Pre-IPOnasdaqprivatemarket.com · 2025
- Biotech begins human trials with drug discovered using AIft.com · 2022
- Alice Zhang’s ‘all-in-human’ AI and genomics upstart scores a $98M Series B – Endpoints Newsendpts.com · 2021
- Verge Genomics Inks Multimillion-Dollar Deal With Lilly To Discover New ALS Drugsforbes.com · 2021
- Verge Genomics Raised 32 million for Data Solutions in Drug Developinghealthcareweekly.com · 2018
- AI Company Verge Genomics Snags $32 Million in Series A Funding - BioSpacebiospace.com · 2018
- Verge Genomics Raises $4M in Seed Financing | GenomeWebgenomeweb.com · 2015